PARP抑制剂临床开发十年回顾
本文综述了PARP抑制剂十年临床开发历程,包括奥拉帕利首次人体试验临床验证了PARP1抑制与BRCA1/BRCA2缺陷的合成致死作用,以及多种PARP抑制剂在乳腺癌和卵巢癌中的注册获批。文章还总结了PARP抑制剂作用机制与耐药机制的研究进展,并讨论了拓展精准医学应用的机会。
要点
- 2009年奥拉帕利首次人体试验临床验证了PARP1抑制与BRCA1/BRCA2缺陷的合成致死作用
- 多种PARP抑制剂已在乳腺癌(奥拉帕利、他拉唑帕利)和卵巢癌(奥拉帕利、尼拉帕利、卢卡帕利)注册
- 文章讨论通过更好预测生物标志物和联合治疗拓展PARP抑制剂精准医学应用的机会
核心结论
- 十年PARP抑制剂临床开发已使多种PARP抑制剂在乳腺癌和卵巢癌注册,并拓展了对作用机制与耐药机制的认识。
研究设计与样本
- 综述类文章,总结PARP抑制剂十年临床开发工作。
主要发现
- 2009年奥拉帕利首次人体临床试验临床验证了PARP1抑制与BRCA1/BRCA2缺陷的合成致死相互作用。
- 奥拉帕利和他拉唑帕利已在乳腺癌注册,奥拉帕利、尼拉帕利和卢卡帕利已在卵巢癌注册,可单用或铂类化疗后维持治疗。
- 过去十年对PARP抑制剂作用机制及肿瘤耐药机制的认识得到扩展。
关键数值与推荐
- 乳腺癌注册药物:奥拉帕利和他拉唑帕利。
- 卵巢癌注册药物:奥拉帕利、尼拉帕利和卢卡帕利,可单用或铂类化疗后维持治疗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Genomic instability is a hallmark of cancer, and often is the result of altered DNA repair capacities in tumour cells. DNA damage repair defects are common in different cancer types; these alterations can also induce tumour-specific vulnerabilities that can be exploited therapeutically. In 2009, a first-in-man clinical trial of the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib clinically validated the synthetic lethal interaction between inhibition of PARP1, a key sensor of DNA damage, and BRCA1/BRCA2 deficiency. In this review, we summarize a decade of PARP inhibitor clinical development, a work that has resulted in the registration of several PARP inhibitors in breast (olaparib and talazoparib) and ovarian cancer (olaparib, niraparib and rucaparib, either alone or following platinum chemotherapy as maintenance therapy). Over the past 10 years, our knowledge on the mechanism of action of PARP inhibitor as well as how tumours become resistant has been extended, and we summarise this work here. We also discuss opportunities for expanding the precision medicine approach with PARP inhibitors, identifying a wider population who could benefit from this drug class. This includes developing and validating better predictive biomarkers for patient stratification, mainly based on homologous recombination defects beyond BRCA1/BRCA2 mutations, identifying DNA repair deficient tumours in other cancer types such as prostate or pancreatic cancer, or by designing combination therapies with PARP inhibitors.
引用
- Mateo J, Lord CJ, Serra V, et al. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol. 2019. PMID: 31218365. doi:10.1093/annonc/mdz192
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。